I-131 CONTAMINATION FROM THYROID-CANCER PATIENTS

被引:0
|
作者
IBIS, E [1 ]
WILSON, CR [1 ]
COLLIER, BD [1 ]
AKANSEL, G [1 ]
ISITMAN, AT [1 ]
YOSS, RG [1 ]
机构
[1] MILWAUKEE CTY MED CTR,RADIAT SAFETY PROGRAM OFF,MILWAUKEE,WI
关键词
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
High-dose radioactive iodine therapy using I-131 is the treatment of choice for patients with thyroid cancer following thyroidectomy. Because of the large amount of activity which is excreted during hospitalization, contamination hazard from I-131 excretion via perspiration, saliva, breath and urine may arise. In eight patients treated with doses of I-131 ranging from 3.7 to 14.8 GBq (1 00-400 mCi), activity levels were measured in room air, from room surfaces, the toilet, the patients' exhaled breath, skin, saliva and toothbrushes, and the gloves used by medical staff. Thyroid bioassays were also performed on medical staff personnel caring for these patients both before and two days after administration of the treatment dose. Removable activity from the skin was positively correlated with treatment dose and reached a maximum at 24 hr post-therapy. Removable activity from room surfaces exceeded the level of contamination which requires clean-up in a restricted area during the patient's hospitalization. Thyroid bioassays on medical staff showed no significant uptake 2 days after treatment. The relatively high activities present in the saliva, urine and on the skin of these patients emphasizes the need for all individuals coming in contact with these patients to be made aware of the contamination hazard present.
引用
收藏
页码:2110 / 2115
页数:6
相关论文
共 50 条
  • [21] LONG-TERM HAZARDS OF I-131 TREATMENT OF THYROID-CANCER
    EDMONDS, CJ
    SMITH, T
    ANNALES D ENDOCRINOLOGIE, 1984, 45 (01) : 83 - 83
  • [22] LOW DOSE-RATE I-131 THERAPY FOR THYROID-CANCER
    SILVA, F
    FLORES, C
    ORDUNA, E
    ROSA, E
    GONZALEZ, R
    JOURNAL OF NUCLEAR MEDICINE, 1994, 35 (05) : P165 - P165
  • [23] DETECTION OF CHROMOSOMAL ABERRATION INDUCED BY I-131 THERAPY FOR THYROID-CANCER
    GOTOH, E
    SEKINE, H
    ASAKAWA, Y
    KAMEOKA, Y
    MORIYA, E
    KAWAKAMI, K
    MOCHIZUKI, S
    JOURNAL OF NUCLEAR MEDICINE, 1993, 34 (05) : P161 - P161
  • [24] PREGNANCY AFTER TOTAL THYROIDECTOMY AND I-131 THERAPY FOR THYROID-CANCER
    PELIZZO, MR
    MANFE, AZ
    CASARA, D
    GIRELLI, ME
    BUSNARDO, B
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1981, 6 (05): : A24 - A24
  • [25] DETERMINATION OF I-131 DIAGNOSTIC DOSE FOR IMAGING METASTATIC THYROID-CANCER
    ARNSTEIN, NB
    CAREY, JE
    SPAULDING, SA
    SISSON, JC
    JOURNAL OF NUCLEAR MEDICINE, 1986, 27 (11) : 1764 - 1769
  • [26] CERVICAL DISTRIBUTION OF I-131 FOLLOWING TOTAL THYROIDECTOMY FOR THYROID-CANCER
    FRATKIN, MJ
    NEWSOME, HH
    SHARPE, AR
    TATUM, JL
    ARCHIVES OF SURGERY, 1983, 118 (07) : 864 - 867
  • [27] THE INDICATIONS FOR ABLATING NORMAL THYROID-TISSUE WITH I-131 IN DIFFERENTIATED THYROID-CANCER
    GOOLDEN, AWG
    CLINICAL ENDOCRINOLOGY, 1985, 23 (01) : 81 - 86
  • [28] SPURIOUS THYROID-CANCER METASTASIS - SALIVA CONTAMINATION ARTIFACT IN HIGH-DOSE I-131 METASTASES SURVEY
    PARK, HM
    TARVER, RD
    SCHAUWECKER, DS
    BURT, R
    JOURNAL OF NUCLEAR MEDICINE, 1986, 27 (05) : 634 - 636
  • [29] THE SIGNIFICANCE OF I-131 SCAN DOSE IN PATIENTS WITH THYROID-CANCER - DETERMINATION OF ABLATION - CONCISE COMMUNICATION
    WAXMAN, A
    RAMANNA, L
    CHAPMAN, N
    CHAPMAN, D
    BRACHMAN, M
    TANASESCU, D
    BERMAN, D
    CATZ, B
    BRAUNSTEIN, G
    JOURNAL OF NUCLEAR MEDICINE, 1981, 22 (10) : 861 - 865
  • [30] CANCER RISKS AFTER DIAGNOSTIC DOSES OF I-131 WITH SPECIAL REFERENCE TO THYROID-CANCER
    HOLM, LE
    CANCER DETECTION AND PREVENTION, 1991, 15 (01): : 27 - 30